The following sections of this review will show alterations of S100B in different disorders (AD, PD, ALS, MS, traumatic and vascular acute brain injury, epilepsy, and inflammatory bowel disease), as well as indicate how alterations of the protein in experimental models of disease correlate with clinical symptoms and/or pathological parameters. Here, S100B is linked to myeloid sarcoma.